Madrigal Pharmaceuticals, Inc.

Is Madrigal Pharmaceuticals, Inc. technically bullish or bearish?

As of October 24, 2025, Madrigal Pharmaceuticals, Inc. shows a mildly bullish technical trend, supported by bullish weekly MACD and Bollinger Bands, despite mixed signals from other indicators, and has significantly outperformed the S&P 500 over the past year and three years.

As of 24 October 2025, the technical trend for Madrigal Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish. The Bollinger Bands indicate a mildly bullish stance on both weekly and monthly time frames. However, the KST shows a bullish weekly signal but a mildly bearish monthly signal, and Dow Theory presents a mildly bearish weekly view alongside a bullish monthly perspective. The daily moving averages are mildly bullish. <BR><BR>In terms of performance, Madrigal has outperformed the S&P 500 significantly over the past year with a return of 107.65% compared to the S&P 500's 16.90%, and over three years with a return of 504.39% against the S&P 500's 78.85%. Overall, the current technical stance is mildly bullish, supported by the weekly MACD and Bollinger Bands, despite mixed signals from other indicators.

Is Madrigal Pharmaceuticals, Inc. overvalued or undervalued?

As of August 7, 2024, Madrigal Pharmaceuticals, Inc. is considered risky and overvalued due to significant negative financial metrics, including a Price to Book Value of 8.69, an EV to Sales ratio of 17.17, and a troubling ROE of -55.10%, despite outperforming the S&P 500 with a 535.91% return over three years.

As of 7 August 2024, the valuation grade for Madrigal Pharmaceuticals, Inc. has moved from does not qualify to risky, indicating increased concerns regarding its financial health. The company appears to be overvalued given its significant negative metrics, including a Price to Book Value of 8.69 and an EV to Sales ratio of 17.17, which suggest that investors are paying a premium despite the lack of profitability. Additionally, the company's ROE stands at a troubling -55.10%, further underscoring its financial challenges.<BR><BR>In comparison to its peers, Madrigal's valuation ratios are starkly unfavorable; for instance, Corcept Therapeutics, Inc. has a P/E ratio of 60.03, while ACADIA Pharmaceuticals, Inc. presents a more attractive P/E of 19.28. The recent stock performance shows that Madrigal has outperformed the S&P 500 over multiple periods, with a remarkable 535.91% return over three years compared to the S&P 500's 70.41%. However, the overall financial metrics suggest that the stock is overvalued in light of its current operational struggles.

How big is Madrigal Pharmaceuticals, Inc.?

As of Jun 18, Madrigal Pharmaceuticals, Inc. has a market capitalization of $6.21 billion, with net sales of $317.38 million and a net profit of -$391.59 million over the latest four quarters. Shareholder's funds are $754.38 million, and total assets amount to $1.04 billion.

As of Jun 18, Madrigal Pharmaceuticals, Inc. has a market capitalization of 6,208.04 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the company reported net sales of 317.38 million for the latest four quarters. During the same period, it recorded a net profit of -391.59 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 754.38 million and total assets amounting to 1,042.25 million.

What does Madrigal Pharmaceuticals, Inc. do?

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). As of March 2025, it reported net sales of $137 million and a net loss of $73 million, with a market cap of approximately $6.21 billion.

Overview: <BR>Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic candidates for cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH) within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Net Sales: 137 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -73 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 6,208.04 Million (Small Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.03 <BR>Return on Equity: -55.10% <BR>Price to Book: 8.74 <BR><BR>Contact Details: <BR>Address: 200 Barr Harbor Dr Ste 400, CONSHOHOCKEN PA: 19428-2978 <BR>Tel: 1 404 3809263 <BR>Fax: 1 302 6555049 <BR>Website: http://www.madrigalpharma.com

Should I buy, sell or hold Madrigal Pharmaceuticals, Inc.?

Who are in the management team of Madrigal Pharmaceuticals, Inc.?

As of March 2022, the management team of Madrigal Pharmaceuticals, Inc. includes Dr. Paul Friedman (CEO), Dr. Rebecca Taub (President of R&D and CMO), and several independent directors: Dr. Frederick Craves, Mr. Kenneth Bate, Mr. James Daly, Mr. Keith Gollust, and Dr. Richard Levy. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Madrigal Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. Paul Friedman: Chairman of the Board and Chief Executive Officer<BR>- Dr. Rebecca Taub: President of Research and Development, Chief Medical Officer, and Director<BR>- Dr. Frederick Craves: Lead Independent Director<BR>- Mr. Kenneth Bate: Independent Director<BR>- Mr. James Daly: Independent Director<BR>- Mr. Keith Gollust: Independent Director<BR>- Dr. Richard Levy: Independent Director<BR><BR>This team is responsible for overseeing the strategic direction and operations of the company.